After 2 years of follow-up, the administered levodopa doses were significantly lower in patients with two parkin mutations compared to patients without mutations and there was also a trend for PD patients with one parkin mutation to receive lower levodopa doses, albeit without reaching statistical significance [50]. This evidence concerns the gene PRKN and Parkinson disease.